- Activity pressure is constructive, supporting the smart-money activity read.
POCI
NASDAQ
Week ended 24 Jul 2026
Weekly Investor Report
Precision Optics Corporation, Inc. Common stock · Healthcare · Medical Instruments & Supplies
Latest close
4.30 USD
-0.9%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -8.8% below the Trend Line and sits at 28.8% of its 52-week range. The latest completed week returned -0.9%, after a -18.7% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 53/100. Near-term considerations: volume confirmation is below normal; earnings are due in 59d.
Setup score
23
out of 100
Latest Close
4.30 USD
24 Jul 2026
1W Return
-0.9%
latest completed week
4W Return
-18.7%
short-term follow-through
12W Return
0.9%
quarterly tape
Trend Breadth
34.6%
18 of 52 weeks active
Volume Ratio
0.4x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-0.9%
Latest completed week; four-week move -18.7%.
Indicator stack
19/39
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
53/100
41 relevant articles in the latest sentiment read.
Event risk
59d
Next report is scheduled for 28 Sep 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -8.8% below the Trend Line and sits at 28.8% of its 52-week range. The latest completed week returned -0.9%, after a -18.7% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.4x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
30 Jan
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.6212-week average 0.36
12-week confirmation
Trend active9/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure9/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership4/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.62Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -18.7% over four weeks, 0.9% over 12 weeks, and -10.4% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year18
Trend breadth34.6%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.13Latest activity-pressure read.
Pressure change-112.0%Four-week change in activity pressure.
Leadership-14.09Latest relative-leadership reading.
RS change-6551.4%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 26 Jul 2026
Financial statements through 30 Jun 2025
Field coverage 82%
Model confidence 78%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength78/100Blend of value, momentum, and quality. Underlying universe rank 23; rank 1 is best.
Value64/100Relative valuation strength. Underlying universe rank 37; rank 1 is best.
Quality62/100Profitability and accounting quality. Underlying universe rank 39; rank 1 is best.
Momentum64/100Medium-term price momentum. Underlying universe rank 37; rank 1 is best.
Growth64/100Revenue and earnings growth. Underlying universe rank 37; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 1.6x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -2.4% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 13.8% Gross profit retained from each unit of revenue.
- Operating margin
- -16.4% Operating profit retained from revenue.
- Free-cash-flow margin
- -3.3% Free cash flow generated from revenue.
- Return on invested capital
- -26.0% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 64.2% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 3/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -22.6% Net share repurchases relative to market value.
- Shareholder yield
- -22.6% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 1.4x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment53/100
Weighted news tone is neutral across 41 relevant articles.
10 positive · 29 neutral · 2 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings59dNext report is scheduled for 28 Sep 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-30.1%Distance below the 52-week high.
13-week volatility6.2%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
30 Jan
27 Feb
27 Mar
24 Apr
22 May
19 Jun
24 Jul
Weeks higher12 of 2614 weeks finished lower.
Best week+13.3%Week of 6 Feb.
Worst week-15.6%Week of 13 Feb.
Latest week-0.9%Week of 24 Jul.
Shape of recent returns
Strong gains5
Modest gains7
Flat weeks0
Modest losses7
Sharp losses7
Recent vol6.2%13-week weekly-return volatility.
Base vol5.7%52-week weekly-return volatility.
Up/down split24/26Count of positive and negative weeks in the 52-week window.
Average skew4.4% / -4.2%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average1.3%
Trend breadth51.0%
Trend51.0%active weekly trend signals
MD75.0%positive activity pressure
RS48.0%positive relative leadership
Four-week leaders
IndustryUS Medical Instruments & Supplies
4-week rank46 / 50
Group average-4.0%
Trend breadth38.0%
Trend38.0%active weekly trend signals
MD76.0%positive activity pressure
RS22.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape26/100
Trend, activity pressure, participation, and risk combine to a 26/100 tape read.
Indicator analysis61/100Latest 12-week confirmation: trend 9/12, activity pressure 9/12, relative leadership 4/12.
Activity pressure 0.62; No reversal markers Factors67/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 92 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment53/100Weighted news tone is neutral across 41 relevant articles.
1 Healthcare Stock to Keep an Eye On and 2 We Avoid Insiders50/100No recent insider transaction evidence is stored.
Earnings59dNext report is scheduled for 28 Sep 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 24 Jul 2026 | 4.30 USD | -0.9% | 4.72 USD | 5.14 USD | -0.13 | -14.09 | 99.2K | Off |
| 17 Jul 2026 | 4.34 USD | -12.9% | 4.71 USD | 5.15 USD | 0.22 | -15.17 | 156.1K | On |
| 10 Jul 2026 | 4.98 USD | -1.6% | 4.70 USD | 5.16 USD | 0.57 | -7.26 | 147.7K | On |
| 3 Jul 2026 | 5.06 USD | -4.3% | 4.68 USD | 5.17 USD | 0.82 | -4.56 | 143.5K | On |
| 26 Jun 2026 | 5.29 USD | -7.5% | 4.65 USD | 5.17 USD | 1.10 | 0.22 | 214.3K | On |
| 19 Jun 2026 | 5.72 USD | -2.9% | 4.63 USD | 5.18 USD | 1.30 | 3.09 | 101.8K | On |
| 12 Jun 2026 | 5.89 USD | 1.6% | 4.59 USD | 5.18 USD | 1.35 | 8.82 | 172.0K | On |
| 5 Jun 2026 | 5.80 USD | 6.6% | 4.54 USD | 5.19 USD | 1.15 | 9.37 | 344.1K | On |
| 29 May 2026 | 5.44 USD | 10.3% | 4.48 USD | 5.19 USD | 0.74 | -2.23 | 371.5K | On |
| 22 May 2026 | 4.93 USD | 3.4% | 4.44 USD | 5.20 USD | 0.12 | -9.06 | 510.0K | On |
| 15 May 2026 | 4.77 USD | 3.9% | 4.42 USD | 5.21 USD | -0.34 | -11.32 | 418.3K | Off |
| 8 May 2026 | 4.59 USD | 7.7% | 4.40 USD | 5.22 USD | -0.43 | -15.36 | 154.1K | Off |
| 1 May 2026 | 4.26 USD | 2.7% | 4.40 USD | 5.23 USD | -0.48 | -17.76 | 47.3K | Off |
| 24 Apr 2026 | 4.15 USD | -4.4% | 4.40 USD | 5.24 USD | -0.34 | -19.12 | 136.9K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.